Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3256  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,433 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Our Experience
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed78    
    Printed1    
    Emailed0    
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2020  |  Volume : 68  |  Issue : 7  |  Page : 39-43

Current Status of Surgery in Management of Prolactinomas


1 Department of Neurosurgery, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India
2 Department of Neurology, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India

Date of Web Publication24-Jun-2020

Correspondence Address:
Dr. Manas K Panigrahi
Department of Neurosurgery, Krishna Institute of Medical Sciences, 1-8-31/1, Ministers Road, Secunderabad, Telangana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.287668

Rights and Permissions

 » Abstract 


Prolactinomas are a complex neuroendocrine challenge for the neurosurgeon. Management of prolactinoma patients requires centres that include neuroendocrinologists, neurosurgeons, neuroradiologists. Although dopamine agonists are the current mainstay of management of prolactinomas, surgery was often preferred management option prior to 1980, before the advent of dopamine agonists. Importantly, all patients with neurologic symptoms suspected due to the lesion, and those risk of adverse effects of medical management, treatment failure, resistance to dopamine agonists and those planning pregnancy, should be referred to a neurosurgeon at the earliest possible. When selected after meticulous evaluation, in patients with neurological deficits like acute visual loss, intolerance to medical therapy, or treatment failures, surgical intervention could come to rescue. Encouragingly, when carefully selected, surgical remission rates are high. In the current review, we review the existing literature and share the experience at our centre in the surgical management of prolactinomas.


Keywords: Dopamine agonists, neuro-endocrinology, neurosurgery, prolactinoma
Key Message: In carefully selected patients, over long-term, surgery for prolactinomas may be both cost-effective and efficient than medical management.


How to cite this article:
Panigrahi MK, Chandrasekhar Y B, Vooturi S. Current Status of Surgery in Management of Prolactinomas. Neurol India 2020;68, Suppl S1:39-43

How to cite this URL:
Panigrahi MK, Chandrasekhar Y B, Vooturi S. Current Status of Surgery in Management of Prolactinomas. Neurol India [serial online] 2020 [cited 2020 Jul 15];68, Suppl S1:39-43. Available from: http://www.neurologyindia.com/text.asp?2020/68/7/39/287668




Prolactinomas, which constitute nearly 40% of all pituitary adenomas are also the most common functional pituitary adenomas.[1] The reported prevalence of prolactinomas is 35 cases per 100,000 population with an annual incidence of 1.6-2.2 per 100,000 people.[2],[3],[4] The incidence of prolactinomas is highest in child-bearing women and inpatients with multiple endocrine neoplasia, type 1.[5] The goals of management of prolactinoma are to prevent neurologic morbidity and avoid derangement of endocrine function. Since managing a patient with a potential prolactinoma begins with correctly interpreting the prolactin level, growing evidence suggests that cut-off values should also consider size/volume of tumor (prolactin per cubic centimetre)[6] and not just absolute prolactin level. In the current review, we will discuss the role of surgery and current trends in neurosurgery for these patients. Additionally, we also report our experience with surgical management of prolactinomas with apt case examples.

Although surgical management was preferred option of treatment of prolactinomas till early 1980, with the advent of dopamine agonists (DA), medical management assumed preference. Case 1 illustrates the role of DA like cabergoline (1 mg per week administered for 4 months) in the medical management of prolactinomas, witnessed by reduction in prolactin levels, improvement in visual fields and radiological improvement [Figure 1]. Although medical management is desirable, the necessity of long-term use of DAs, costs of medical management over long term, resistance and/or intolerance to DAs and requirement of continuous monitoring of prolactin levels form few drawbacks of long-term medical management. Additionally, in subsets of patients, like those with hyperprolactinemia, macro-prolactinomas and prolactinomas destructing the sella surgical management should be considered at the earliest possible. Additionally, women with prolactinomas (irrespective of the size of prolactinoma) planning pregnancy should prefer surgical management. Therefore, each prolactinoma should be treated on an individual case basis. [Table 1] summarizes indications where surgery may perhaps be the preferred option.
Figure 1: Magnetic resonance imaging (plain and contrast) to assess the role of Cabergoline.

Click here to view
Table 1: Indications for surgery in prolactinomas

Click here to view


  1. Avoiding the need for life-long medication and long-term cost-efficiency
  2. Planned pregnancy
  3. Apoplexy and/or cystic prolactinomas
  4. Prolactinoma with acute onset of neurologic deficits including visual loss
  5. Are intolerant to DA, as measured by significant subjective symptoms
  6. DA resistant prolactinoma (DARP) [Figure 1]
  7. Recurrent prolactinomas, despite optimal medical management.


It is important that patient preference should always be respected, but it is advisable to explain the patients about benefits of medical therapy too. Importantly, the safety of the surgical cure should be explained to patients before scheduling surgery. Most often reported reasons for preference of surgery over medication in our practise are:

1. Avoiding the need for lifelong medication and cost-effectiveness

Current guidelines advise DAs for at least two years after normalization of hyperprolactinemia, followed by gradual tapering (to reduce side-effects).[7] It should be noted that if DAs are discontinued, the reported rates of recurrence in 18 months are nearly 60%.[8]

Therefore there is need for long term use of DAs in these patients, leading to increased costs incurred both due to medications and frequent screening of prolactin levels and radiological investigations as required. In fact, Zygourakis C C et al.[9] have recently shown that in an average patient, if diagnosed of prolactinoma at an age of 40 years, lifetime cost of surgical management was 40.473 dollars. While the lifetime cost for 41,601 dollars for bromocriptine, it was 70,696 dollars for those prescribed cabergoline. Therefore, when carefully selected, surgery if more cost-effective management option. However, while elaborating the role of surgery as a definitive management, it should be explained to the patient that if surgery results in hypopituitarism or a residual lesion, DA therapy will be considered post-operatively, even if not previously attempted.

2. Plan pregnancy

Since the normalization of prolactin and resumption of menstrual cycles can take several months after initiating DA therapy, surgery is preferred in patients who plan pregnancy in near future. However, in these patients, guidelines suggest that surgical option should be undertaken only after failure of DA agents like cabergoline, especially despite failure of bromocriptine.[10] Nayan Lamba et al.[11] have very recently reported that in patients with prolactinomas, surgical management significantly improved the chances of fertility. Importantly, symptomatic enlargement of microprolactinomas in 5% and enlargement of macroprolactinomas in 35% pregnant patients with prolactinomas necessitated surgical management of prolactinomas. Especially in pregnant women with macroprolactinomas, increase in the size of prolactinoma may result in worsening of neurological deficits and vision loss, which may lead to untoward incidents. Hence, surgical removal of prolactinomas could be the management of choice in women desiring pregnancy.

3. Prolactinoma with Apoplexy and cystic prolactinomas

In patients with prolactinoma with apoplexy, acute changes in size are often reported during the apoplectic event with resultant neurologic compromise [Figure 2] and [Figure 3]. Optimal interventions should aim to change the size of the prolactinoma. Therefore, surgery has evolved as the recommendation for patients with symptomatic prolactinoma with apoplexy. Importantly, it is now well established that patients with pituitary adenomas and apoplexy should undergo neurosurgery at the earliest possible. Furthermore, timing of surgery in prolactinoma with apoplexy is similar to the urgency as in other types of pituitary adenomas. Similarly, in patients with cystic prolactinomas affecting/intruding the sella, surgical management should be the treatment of choice [Figure 2]. Current literature in patients with cystic prolactinomas reports more severe symptoms in these patients possibly due to the mass effect of “hypocellular” cyst. Studies have also reported these patients be “less responsive to DA”. Faje et al.[12] reported their findings in 30 patients with cystic prolactinomas. Among the 30 patients, 22 underwent DA therapy and eight had surgery. The authors reported that 33% of patients in the DA- first group ultimately required surgery, which included three patients whose cysts grew. On the contrary, all patients undergoing surgery had optic chiasm decompression and reduction in cyst volume. Therefore, current guidelines recommend that surgery should the choice of intervention in these patients.[1]
Figure 2: Example of a prolactinoma with destruction of skull base

Click here to view
Figure 3: Findings on MRI of a Cystic prolactinoma with apoplexy

Click here to view


4. Prolactinoma with Visual Loss or Other Neurologic Deficits

Another scenario where surgical intervention is opted includes, prolactinoma patients with neurologic deficits (visual field deficits or cranial neuropathies), that are often reported in the subacute period without apoplexy. If meticulously managed at optimal dosages, when carefully selected, these patients may respond to medical management. However, patients in this subset are probably the best candidates for neurosurgical intervention. Therefore, the authors opine that all patients with prolactinomas and neurologic deficits should undergo neurosurgical consult. Patients who are too sick to undergo surgery, those who opt to avoid surgery and patients with early visual changes, medical management should be attempted.

5. Surgery after Dopamine Agonist Therapy – Intolerance

In most patients, DAs are well tolerated. However, the adverse effects from DA administration, documented in the literature, are often dose-dependent, especially due to the need to take these medications for many years. In patients treated with bromocriptine; 78% of patients experienced adverse effects with resultant discontinuation reported in 5% of patients.[13]

Among other DAs, though less frequent, cabergoline is associated with headaches and rare adverse events such as intratumoral haemorrhage and cerebrospinal fluid,[13] Case illustration - 2. Importantly, a small sub-set of patients are intolerant to both DA medications, making them ideal for surgical management. Importantly, in patients treated with cabergoline, while 8% had DA intolerance, the reported rates of DA resistance were marginally high at 10%. Similarly, in patients treated with bromocriptine, while DA intolerance was reported in 14% patients, DA resistance was observed in 18%. It is therefore very important to both differentiate and correctly identify intolerance and resistance to DA in these patients.

6. Dopamine Agonist Resistant Prolactinomas (DARP)[14]

In a sub-set of patients, despite optimal dosages of DA (2 mg of cabergoiline per week for three months or 15 mg of bromocriptine per day), failure to demonstrate normalization of prolactin levels or achieve levels of ovulation or enable 50% reduction of hyperprolactinemia size are observed. This sub-set of patients are categorized as DA resistant prolactinomas (DARP), an accepted criteria for considering surgery [Figure 4]. In fact, almost half of surgical cases are after DA treatment failure. Additionally, 15.6% patients have a mixture of treatment failure and adverse effect intolerance. Encouragingly, surgical results in these patients are reportedly favourable, with 60.7% achieving normal prolactin levels. However, more than one-third of patients did not achieve prolactin normalization, this is often attributed to residual tumor which requires radiation. Case 4 illustrates a patient with increase in size of prolactinoma despite optimal medical management.
Figure 4: Dopamine agonist resistant prolactinomas

Click here to view


7. Surgery for Recurrent Prolactinomas

Although very rare, recurrent and aggressive prolactinoma is a treatment challenge. Most of these patients may be effectively treated using the multimodal strategy.[14] Importantly, all patients with prolactinoma undergoing radiation therapy after surgical therapy should be closely monitored, and chemotherapy should be considered. Although prolactinomas rarely progress to pituitary carcinoma, when progressed, they often have extremely elevated MIB-1 and p53 expression and have a poor long-term prognosis.[15],[16] Andereggen L et al.[17] have reported that the primary therapeutic strategy, but not adenoma size, was an independent risk factor for long-term dependence on dopamine-agonists. The authors in this comparative study reported that at final follow-up at 90 months, control of hyper-prolactinaemia required dopamine-agonist therapy in 64 % of women who had undergone primary medical therapy vs. 32 % of those who had primary surgical therapy (P = 0.003). The authors summarized that surgical management offered better control of prolactin levels than medical management.


 » Our Experience Top


In our centre, over the last 10 years, out of the 452 patients diagnosed with pituitary adenomas, 62 (13.7%) underwent surgery for prolactinoma. Representative images of the various indications for surgery for prolactinomas from our series of patients is illustrated as [Figure 1], [Figure 2], [Figure 3], [Figure 4] of the article.


 » Conclusion Top


Although, medical management using DA therapy is most widely used in patients with prolactinomas, patients who have neurologic symptoms related to the lesion and those at risk for treatment failure should be referred to a neurosurgeon. Surgical management should be strongly considered, in selected patients with prolactinoma with acute visual loss, or those intolerant to medical therapy, or with documented treatment failures and especially in patients with resistance to DA. Additionally, surgery is useful in women with prolactinomas who desire pregnancy/fertility. In carefully selected patients, over long-term, surgery for prolactinomas is not only more cost-effective than medical management with DA but also offers better control of prolactin levels.[18-20]

Case illustrations

Case 1 illustrates the case of a 48-year-old male patient with a prolactinoma who showed Reduction in tumor size in response to cabergoline.

Case 2 illustrates the case of a 25-year-old male initial managed with medical treatment [Figure 2]a, but later on patient presented with CSF rhinorrhoea. Although in MRI there was reduction of lesion of size of tumor patient underwent surgery [Figure 2]b and [Figure 2]c.

Case 3 A 26-year-old female patients with cystic pituitary tumor [Figure 3] with high serum prolactin level was not responded with medical treatment and later on underwent surgical treatment.

Case 4 illustrates the case of a 33-year-old female patient with a prolactinoma [Figure 4]a who showed increase in tumor size despite optimal medical management using cabergoline (reduction in serum prolactin level) [Figure 4]b. This patient underwent surgical management due to increase in size of tumor.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73.  Back to cited text no. 1
    
2.
Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: A population based study in Malta. Pituitary 2013;16:545-53.  Back to cited text no. 2
    
3.
Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010;95:4268-75.  Back to cited text no. 3
    
4.
Tjornstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol 2014;171:519-26.  Back to cited text no. 4
    
5.
de Laat JM, Dekkers OM, Pieterman CR, Kluijfhout WP, Hermus AR, Pereira AM, et al. Long-term natural course of pituitary tumors in patients with MEN1: Results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab 2015;100:3288-96.  Back to cited text no. 5
    
6.
Huang Y, Ding C, Zhang F, Xiao D, Zhao L, Wang S. Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas. Oncol Lett 2018;15:2010-6.  Back to cited text no. 6
    
7.
Paepegaey AC, Salenave S, Kamenicky P, Maione L, Brailly-Tabard S, Young J, et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc 2017;1:221-30.  Back to cited text no. 7
    
8.
Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009;94:2428-36.  Back to cited text no. 8
    
9.
Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, et al. Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg B Skull Base 2017;78:125-31.  Back to cited text no. 9
    
10.
Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010;95:2672-9.  Back to cited text no. 10
    
11.
Lamba N, Noormohamed N, Simjian T, Alsheikh MY, Jamal A, Doucette J, et al. Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis. Clin Neurol Neurosurg 2019;176:53-60.  Back to cited text no. 11
    
12.
Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A. Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab 2016;101:3709-15.  Back to cited text no. 12
    
13.
Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338-43.  Back to cited text no. 13
    
14.
Donoho DA, Laws ER Jr. The role of surgery in the management of prolactinomas. Neurosurg Clin N Am 2019;30:509-14.  Back to cited text no. 14
    
15.
Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R, et al. Invasive adenoma and pituitary carcinoma: A SEER database analysis. Neurosurg Rev 2014;37:279-85; discussion 285-6.  Back to cited text no. 15
    
16.
Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, et al. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones (Athens) 2012;11:477-82.  Back to cited text no. 16
    
17.
Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 2017;55:223-30.  Back to cited text no. 17
    
18.
Sinha S, Sharma BS, Mahapatra AK. Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases. Neurol India 2011;59:532-6.  Back to cited text no. 18
[PUBMED]  [Full text]  
19.
Behari S. Management of prolactinomas: the fine print between the lines. Neurol India 2011;59:501-3.   Back to cited text no. 19
[PUBMED]  [Full text]  
20.
Vivekanandan S, Nayak D. Microsurgical management of prolactinomas - clinical and hormonal outcomes. Neurol India 2011;59:944-5.  Back to cited text no. 20
  [Full text]  


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow